EDITAS MEDICINE INC (EDIT) Stock Fundamental Analysis

NASDAQ:EDIT • US28106W1036

1.77 USD
-0.04 (-2.21%)
Last: Feb 20, 2026, 12:51 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

EDIT gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. EDIT may be in some trouble as it scores bad on both profitability and health. EDIT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • EDIT had negative earnings in the past year.
  • In the past year EDIT has reported a negative cash flow from operations.
  • In the past 5 years EDIT always reported negative net income.
  • In the past 5 years EDIT always reported negative operating cash flow.
EDIT Yearly Net Income VS EBIT VS OCF VS FCFEDIT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

  • EDIT has a Return On Assets of -99.05%. This is in the lower half of the industry: EDIT underperforms 74.09% of its industry peers.
  • EDIT has a worse Return On Equity (-1485.43%) than 80.42% of its industry peers.
Industry RankSector Rank
ROA -99.05%
ROE -1485.43%
ROIC N/A
ROA(3y)-47.65%
ROA(5y)-38.33%
ROE(3y)-93.86%
ROE(5y)-69.16%
ROIC(3y)N/A
ROIC(5y)N/A
EDIT Yearly ROA, ROE, ROICEDIT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for EDIT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EDIT Yearly Profit, Operating, Gross MarginsEDIT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • EDIT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • EDIT has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, EDIT has more shares outstanding
  • EDIT has a worse debt/assets ratio than last year.
EDIT Yearly Shares OutstandingEDIT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
EDIT Yearly Total Debt VS Total AssetsEDIT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of -11.74, we must say that EDIT is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -11.74, EDIT is not doing good in the industry: 75.62% of the companies in the same industry are doing better.
  • EDIT has a Debt/Equity ratio of 4.02. This is a high value indicating a heavy dependency on external financing.
  • EDIT has a worse Debt to Equity ratio (4.02) than 80.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.02
Debt/FCF N/A
Altman-Z -11.74
ROIC/WACCN/A
WACC8.41%
EDIT Yearly LT Debt VS Equity VS FCFEDIT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 2.86 indicates that EDIT has no problem at all paying its short term obligations.
  • EDIT's Current ratio of 2.86 is on the low side compared to the rest of the industry. EDIT is outperformed by 65.83% of its industry peers.
  • A Quick Ratio of 2.86 indicates that EDIT has no problem at all paying its short term obligations.
  • EDIT has a Quick ratio of 2.86. This is in the lower half of the industry: EDIT underperforms 63.72% of its industry peers.
Industry RankSector Rank
Current Ratio 2.86
Quick Ratio 2.86
EDIT Yearly Current Assets VS Current LiabilitesEDIT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 7.03% over the past year.
  • Looking at the last year, EDIT shows a very negative growth in Revenue. The Revenue has decreased by -24.90% in the last year.
  • The Revenue has been growing by 9.50% on average over the past years. This is quite good.
EPS 1Y (TTM)7.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.67%
Revenue 1Y (TTM)-24.9%
Revenue growth 3Y8.16%
Revenue growth 5Y9.5%
Sales Q2Q%12265.57%

3.2 Future

  • The Earnings Per Share is expected to grow by 10.43% on average over the next years. This is quite good.
  • Based on estimates for the next years, EDIT will show a very negative growth in Revenue. The Revenue will decrease by -24.68% on average per year.
EPS Next Y28.81%
EPS Next 2Y26.41%
EPS Next 3Y18.11%
EPS Next 5Y10.43%
Revenue Next Year-38.92%
Revenue Next 2Y-35.9%
Revenue Next 3Y-28.35%
Revenue Next 5Y-24.68%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
EDIT Yearly Revenue VS EstimatesEDIT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 50M 100M 150M
EDIT Yearly EPS VS EstimatesEDIT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -5 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for EDIT. In the last year negative earnings were reported.
  • Also next year EDIT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EDIT Price Earnings VS Forward Price EarningsEDIT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EDIT Per share dataEDIT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as EDIT's earnings are expected to grow with 18.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.41%
EPS Next 3Y18.11%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • EDIT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EDITAS MEDICINE INC

NASDAQ:EDIT (2/20/2026, 12:51:53 PM)

1.77

-0.04 (-2.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19
Earnings (Next)05-11
Inst Owners47.29%
Inst Owner Change7.89%
Ins Owners0.19%
Ins Owner Change-0.1%
Market Cap172.79M
Revenue(TTM)46.38M
Net Income(TTM)-199.84M
Analysts74
Price Target5.32 (200.56%)
Short Float %11.78%
Short Ratio6.48
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.23%
Min EPS beat(2)-63.79%
Max EPS beat(2)7.33%
EPS beat(4)1
Avg EPS beat(4)-40.18%
Min EPS beat(4)-63.79%
Max EPS beat(4)7.33%
EPS beat(8)3
Avg EPS beat(8)-15.9%
EPS beat(12)6
Avg EPS beat(12)-7.53%
EPS beat(16)10
Avg EPS beat(16)-3.06%
Revenue beat(2)2
Avg Revenue beat(2)78.71%
Min Revenue beat(2)47.32%
Max Revenue beat(2)110.1%
Revenue beat(4)3
Avg Revenue beat(4)174.34%
Min Revenue beat(4)-6.91%
Max Revenue beat(4)546.84%
Revenue beat(8)4
Avg Revenue beat(8)133.14%
Revenue beat(12)7
Avg Revenue beat(12)116.99%
Revenue beat(16)10
Avg Revenue beat(16)100.47%
PT rev (1m)5.61%
PT rev (3m)30.36%
EPS NQ rev (1m)-0.59%
EPS NQ rev (3m)-6.47%
EPS NY rev (1m)0.41%
EPS NY rev (3m)2.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)24.12%
Revenue NY rev (1m)0%
Revenue NY rev (3m)21.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.73
P/FCF N/A
P/OCF N/A
P/B 12.84
P/tB 12.84
EV/EBITDA N/A
EPS(TTM)-2.38
EYN/A
EPS(NY)-1.16
Fwd EYN/A
FCF(TTM)-1.85
FCFYN/A
OCF(TTM)-1.84
OCFYN/A
SpS0.48
BVpS0.14
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -99.05%
ROE -1485.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.65%
ROA(5y)-38.33%
ROE(3y)-93.86%
ROE(5y)-69.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 4.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.57%
Cap/Sales 2.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.86
Quick Ratio 2.86
Altman-Z -11.74
F-Score2
WACC8.41%
ROIC/WACCN/A
Cap/Depr(3y)98.25%
Cap/Depr(5y)126.71%
Cap/Sales(3y)18.09%
Cap/Sales(5y)18.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.67%
EPS Next Y28.81%
EPS Next 2Y26.41%
EPS Next 3Y18.11%
EPS Next 5Y10.43%
Revenue 1Y (TTM)-24.9%
Revenue growth 3Y8.16%
Revenue growth 5Y9.5%
Sales Q2Q%12265.57%
Revenue Next Year-38.92%
Revenue Next 2Y-35.9%
Revenue Next 3Y-28.35%
Revenue Next 5Y-24.68%
EBIT growth 1Y47.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.79%
EBIT Next 3Y15.21%
EBIT Next 5YN/A
FCF growth 1Y-15.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.01%
OCF growth 3YN/A
OCF growth 5YN/A

EDITAS MEDICINE INC / EDIT FAQ

Can you provide the ChartMill fundamental rating for EDITAS MEDICINE INC?

ChartMill assigns a fundamental rating of 1 / 10 to EDIT.


What is the valuation status for EDIT stock?

ChartMill assigns a valuation rating of 0 / 10 to EDITAS MEDICINE INC (EDIT). This can be considered as Overvalued.


How profitable is EDITAS MEDICINE INC (EDIT) stock?

EDITAS MEDICINE INC (EDIT) has a profitability rating of 0 / 10.


How financially healthy is EDITAS MEDICINE INC?

The financial health rating of EDITAS MEDICINE INC (EDIT) is 2 / 10.